Navigation Links
FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
Date:11/13/2013

s cause blood flow problems, which can lead to severe pain, irreversible organ damage, and early death.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014. More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements

Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to the Company's development plans for MST-188 in acute limb ischemia, including its planned phase 2 clinical study in acute limb ischemia, and the potential application of MST-188 in stroke and other indications in which thrombolytic agents are used.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future nonclinical and clinical studies of MST-188 and the risk that MST-188 may not demonstrate adequate safety, efficacy or tolerability in one or more such studies; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," or suspension or termination o
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Commission Designates MST-188 As An Orphan Medicinal Product
2. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
3. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
4. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
5. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
6. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
7. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
8. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
9. Orphan Drugs for Cancer: R&D and Market 2013-2023
10. Epizyme Receives Orphan Drug Designation for EPZ-5676
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... , Sept. 1, 2014 Reportbuyer.com has ... Brazil Aesthetic Lasers and Energy Devices Market ... https://www.reportbuyer.com/product/2343455/Brazil-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Brazil Aesthetic Lasers and ... Summary GlobalData,s new report, "Brazil ... 2020", provides key market data on the Brazil ...
(Date:9/1/2014)... 2014 Reportlinker.com announces ... in its catalogue: Antibody Drug Conjugates ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html INTRODUCTION ... of therapeutic agents, gaining increasing attention from both ... the marriage of an antibody with a toxic ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue:  Drug Discovery Technologies - A Global ... The development of new drugs ... extensive expenditure, in addition to consuming a lot ... new drug involves the utilizing high-throughput screening of ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... GOLDEN, Colo., Nov. 9 ABR-Affinity,BioReagents, a leading ... again exhibit at Medica in Dusseldorf, Germany. ... with over 137,000,visitors expected from all parts of ... BioReagents. The exposure is global, and it is ...
... Nov. 9 This week, Dr. Fouad,Bachour, ... Hennepin County,Medical Center, presented results of a ... http://www.sessionsdailynews.com/tuesday.pdf ) meeting in Orlando showing,that alerting ... a heart attack,patient arrives improves door-to-balloon times ...
Cached Medicine Technology:ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007 2Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients 2
(Date:9/1/2014)... 2014 Building on the success of ... Sleep and Breathing Academy (ASBA) has officially announced ... Healthcare Professionals. The event will be taking place at ... and 11th. This years’ event promises to be yet ... , In recent years, Pro Player Health ...
(Date:9/1/2014)... regular family meals may help protect teens from the ... suggests. Online abuse can lead to depression, anxiety ... five adolescents experience cyberbullying," Frank Elgar, a professor at ... University in Montreal, said in a university news release. ... and abuse are difficult for parents and educators to ...
(Date:9/1/2014)... with action and sound may be bad for your ... grapes while watching an excerpt from a Hollywood action ... Television has been blamed for helping Americans to gain ... focus of why has been on the medium and ... that can cause people to eat more, including reading, ...
(Date:9/1/2014)... with mental health and substance use problems in ... from the consequences of cyberbullying and also be ... J. Elgar, Ph.D., of McGill University, Montreal, Canada, ... adolescents has experienced recent online bullying and cyberbullying, ... mental health problems in teens as well as ...
(Date:9/1/2014)... September 02, 2014 Renal cell carcinoma (RCC) ... lining of the proximal convoluted tubule, a part of the ... from the blood to the urine. The condition is asymptomatic ... RCC are often in the advanced stages of the disease ... RCC often include blood in the urine, flank pain, a ...
Breaking Medicine News(10 mins):Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 2Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 4Health News:Family Meals May Defuse Cyberbullying's Impact, Study Says 2Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 2Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 4
... Can Reveal Blockages Prior to Stroke, CLEVELAND, Oct. ... Kennedy had removed today, are a significant risk factor,for ... the life-threatening,condition. Doppler ultrasound screening is a successful tool ... a stroke and before death or,disability occurs. Life ...
... 12 ABR -- Affinity,BioReagents, a leading global ... website at http://www.bioreagents.com . Re-launched with ... several enhancements which combine to make the customer,s,experience ... to,Ken Wilczek, President of ABR, "We solicited feedback ...
... 50%, study found, , , FRIDAY, Oct. 12 (HealthDay News) -- ... once a week can increase your risk of developing asthma, ... are a direct cause of asthma, or simply a trigger ... this epidemiological study. , However, the European team involved in ...
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading provider of system ... 18 to discuss the,company,s third quarter financial results. What: ... When: October 18, 2007, 2:30 p.m. PDT, ... officer ...
... TO COMMENT ON THE MARKET FORECAST FOR THE DRUG, ... Ph.D., analyst,at Decision Resources, is available to discuss the ... of Merck,s Isentress, the,first integrase inhibitor drug which blocks ... new cells. Integrase inhibitors are a novel class ...
... WARRENDALE, Pa., Oct. 12 Helping its,employees to live ... SAE,International. Recently, the American Heart Association (AHA) recognized,SAE for ... Fit Friendly Company, an honor,presented to only a handful ... What does it mean? In short, it means ...
Cached Medicine News:Health News:Asymptomatic Carotid Artery Blockage a Significant Stroke Risk 2Health News:ABR -- Affinity BioReagents Announces Launch of New Website 2Health News:Home Spray Cleaners Could Raise Asthma Risk 2Health News:Home Spray Cleaners Could Raise Asthma Risk 3Health News:Omnicell Schedules Third Quarter Earnings Call 2Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2
... is,a no-extraction, solid-phase 125I,radioimmunoassay ... use in the quantitative,measurement ... for the,differential diagnosis of ... ovulation induction with,and without ...
... Generation Estradiol EIA is intended ... Estradiol measurements are used in ... various hormonal sexual disorders and ... complicated pregnancy. This assay is ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
... high-throughput immunoassay system built around the many ... the important addition of Logic Driven Incubation ... designed for optimal performance with the fastest ... assays such as the cardiac biomarkers and ...
Medicine Products: